Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference
28 Februar 2023 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a
biopharmaceutical company focused on discovering and developing
potential best-in-class medicines for serious and rare diseases,
today announced that senior management will present at Cowen’s 43rd
Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30
p.m. ET in Boston, MA.
A live webcast of the presentation can be accessed under “Events
and Presentations” on the Investors section of the Viridian website
at viridiantherapeutics.com. A replay of the webcast will be
available following the completion of the event.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
recently initiated its first global Phase 3 trial called ‘THRIVE’
to evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its intravenously administered VRDN-001 program, the Company is
advancing two candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn.
Investor and Media Contacts:Viridian
Therapeutics, Inc.
Louisa Stone, 617-272-4604Manager, Investor
RelationsIR@viridiantherapeutics.com
Todd James, 617-272-4691Senior Vice President, Corporate Affairs
and Investor RelationsIR@viridiantherapeutics.com
Matt Fearer, 617-272-4605Vice President, Corporate
CommunicationsMedia@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024